Introduction
Recent advances in transplantation biology and immunology have resulted in allogeneic hematopoietic SCT becoming a more promising intervention for both malignant and non-malignant diseases. 1 However, pulmonary complications after hematopoietic SCT remain a major cause of mortality and morbidity [2] [3] [4] [5] [6] [7] both in adult and pediatric patients. Pulmonary complications include infectious or non-infectious causes, defined as early and late according to the time of onset after transplantation.
Late-onset non-infectious pulmonary complications (LONIPCs) is the generic description of various pathologies that start to appear at around 90 days after transplant, and include bronchiolitis obliterans (BO), bronchiolitis obliterans with organizing pneumonia (BOOP) and idiopathic pneumonia syndrome (IPS). 8, 9 The incidence of LONIPCs is 10-25% and they are closely associated with TRM. 8, 10, 11 The pathogenesis of LONIPCs has not been elucidated, but their development is consistently associated with the presence of chronic GVHD, [10] [11] [12] [13] [14] [15] [16] indicating that allo-immune reactions play a major role in the development of LONIPCs.
Most publications about LONIPCs describe adult patients. However, information about LONIPCs in pediatric patients is required because the incidence and severity of other complications, such as GVHD, differ between children and adults. Therefore, we retrospectively analyzed the incidence, risk factors and clinical outcome of LONIPCs in 97 pediatric patients who survived for over 3 months after allogeneic hematopoietic SCT.
Materials and methods
Between April 1997 and May 2007, 114 patients underwent allogeneic hematopoietic SCT at the Department of Pediatrics, Nagoya University Hospital. Patients who were 418 years old, who died within 90 post-transplant days or who did not undergo conditioning before transplantation (such as those with SCID syndrome) were excluded. Only data from the first allogeneic transplant were included in this analysis when the patients underwent multiple transplants. We studied the remaining 97 pediatric patients with hematological malignancies (n ¼ 39), non-malignant hematological disorders (n ¼ 55) and solid tumors (n ¼ 3), who met the inclusion criteria. One patient had received an autologous transplant before an allogeneic transplant.
Hematological malignancies and solid tumors not in remission were defined as a high-risk group, whereas all other conditions were defined as a low-risk group. Conditioning regimens classified into TBI (10-12 Gy divided into four fractions)-based myeloablative, high-dose chemotherapy-based myeloablative and reduced-intensity regimens. 17 Supportive care had been relatively consistent throughout the study's 10-year time span. All patients received trimethoprim-sulfamethoxazole orally or inhaled pentamidine as prophylaxis against Pneumocystis jiroveci. Patients received standard doses of oral amphotericin B and acyclovir as fungal and viral prophylaxis. Peripheral blood was obtained weekly from engraftment to discharge to test for CMV antigenemia. Patients received pre-emptive therapy with ganciclovir when the test became positive. During the study period, weekly viral studies for CMV, EBV and human herpesvirus 6 have been conducted until 90 post-transplant days.
18 G-CSF was started from day 5 to neutrophil engraftment in patients, except those with myeloid malignant diseases. Engraftment day was defined as the first of the 3 consecutive days in which the patient had an ANC 40.5 Â 10 9 /l. Failure to engraft by day 30 was considered as primary graft failure.
Acute and chronic GVHD was diagnosed and graded according to the established criteria. 19, 20 GVHD prophylaxis comprised tacrolimus (i.v. infusion of 0.02 mg/kg/day starting on day À1, with dose adjustments to maintain blood levels of 5-15 ng/ml) or CY (i.v. infusion of 3 mg/kg/day starting on day À1, with dose adjustments to maintain trough blood levels at 100-200 ng/ml) with shortterm MTX (15 mg/m 2 on day þ 1 and 10 mg/m 2 on days þ 3, þ 6 and þ 11). The administration route of both drugs was switched to oral after the patients recovered from gastrointestinal toxicity.
Permission for the review of the patients' records and data collection for analysis was obtained from the institutional ethical committee of Nagoya University Graduate School of Medicine.
Diagnosis and classification of LONIPCs
We diagnosed LONIPCs if patients developed respiratory clinical symptoms and the radiological findings showed lung disease without evidence of bacterial, viral, protozoal or fungal infections. Infections were excluded by negative standard culture and histochemical findings. Bronchoalveolar lavage was performed whenever possible, but open or transbronchial lung biopsies were not obtained from any of the patients.
The patients were further classified as having BO, BOOP or IPS according to the clinical, radiological and pulmonary function test findings. 8, 11, 21 Patients were classified as having BO when dyspnea, cough or/and exercise intolerance was accompanied by the chest computed tomography (CT) findings of areas of patchy hyperaeration, bronchial dilation, and hypoattenuation or increased density. Obstructions were indicated as pulmonary function findings of a decline in forced expiratory volume (FEV1) to o80% of predicted value and an FEV1/forced vital capacity o70% of the predicted value. Patients were diagnosed with BOOP if the CT scan showed peripherally distributed patchy air space consolidation and nodular opacities with negative cultures of broncho-alveolar lavage fluid. Patients were diagnosed with IPS if there were chest X-ray and CT findings of bilateral diffuse parenchymal interstitial/alveolar infiltrate in the absence of infectious signs.
Responses to treatment were defined as complete if the clinical and radiological signs of LONIPCs were resolved and those of FEV1 or forced vital capacity became normalized or improved by 450% compared with that at diagnosis of LONIPCs, non-response if no improvement was evident or signs of LONIPCs persisted and partial in the remainder. We estimated the response 4 weeks after the start of the therapy.
Statistical methods
We statistically analyzed risk factors associated with the development of LONIPCs. The pre-transplantation variables included patient age and underlying disease. Transplantation-related variables included ABO blood type incompatibility, use of TBI, BU, fludarabine, anti-thymocyte globulin and G-CSF, intensity of conditioning regimen, GVHD prophylaxis and HLA disparity. HLA-A, B and Cw were typed serologically and DRB1 was typed by a molecular method. We considered HLA disparity as a binary variable for risk-factor analysis. The HLA-less matched group included patients transplanted from related donors with X2 Ag mismatches, unrelated cords with X2 Ag mismatches and unrelated BM donors with X1 Ag mismatches. Patients transplanted with graft sources from other donors were defined as the HLA-better matched group.
Predictors for the occurrence of LONIPCs were evaluated by univariate and multivariate analysis using the Cox regression model. A multivariate model was constructed with forward stepwise methods using threshold P-values of 0.10 for removal or addition to the model. Values of Po0.05 were considered statistically significant. Survival was estimated using the Kaplan-Meier method and differences were assessed using the log-rank test. All analyses were performed using SPSS 15.0 (SPSS, Chicago, IL, USA). Table 1 shows characteristics of the patients. Of the 97 patients who survived for more than 90 days after SCT, 10 (10.3%) developed LONIPCs. Table 2 shows their pretransplant characteristics and clinical outcomes. The median duration from hematopoietic SCT to a diagnosis of LONIPCs was 187 days (range, 123-826 days). Patient 9 received donor lymphocyte infusion at 455, 474 and 495 post-transplant days after relapse of acute myelogenous leukemia and subsequently developed acute and chronic GVHD, followed by LONIPCs at day 659. Patient 7 and 9 had a relapse of leukemia after developing LONIPCs. Of the 10 patients who developed LONIPCs, eight and two were diagnosed with BO and IPS, respectively. No patients were diagnosed with BOOP. Two patients with IPS Non-infectious pulmonary complication in children N Nishio et al required mechanical ventilation and broncho-alveolar lavage findings showed that neither of them had an infection. Table 2 also shows the treatment for 10 patients who developed LONIPCs. Among the patients with BO, five 
Results

Use of G-CSF Yes 77
Use of ATG Yes 40
Use ofBU Yes 28
Use of fludarabine Yes 36 Tacrolimus+sMTX  67  CY+sMTX  24  Others  6 Abbreviations: AA ¼ aplastic anemia; ATG ¼ anti-thymocyte globulin; MDS ¼ myelodysplastic syndrome; sMTX ¼ short-term methotrexate.
GVHD prophylaxis
Non-infectious pulmonary complication in children N Nishio et al received 1-2 mg/kg prednisolone sodium succinate i.v., and a combination of inhaled steroids and bronchodilators was started in addition to CY or tacrolimus for the other three (all eight had already received CY or tacrolimus as prophylaxis against GVHD until the diagnosis of LONIPCs). Clinical symptoms such as dyspnea improved, whereas pulmonary function test and chest CT findings did not improve in the three patients administered with inhaled steroids and bronchodilators. Two patients with IPS received high-dose methylprednisolone therapy, but IPS progressed in both. Overall, only two patients with BO among the 10 with LONIPCs partially responded to prednisolone. Table 3 shows the risk factors for developing LONIPCs. Univariate analysis showed that high-risk underlying disease, BU, acute GVHD II-IV, chronic GVHD and extensive chronic GVHD were significant risk factors for developing LONIPCs. Multivariate analysis confirmed that high-risk underlying disease and extensive chronic GVHD were significant risk factors. Patient age, use of TBI, reduced-intensity regimen or type of GVHD prophylaxis were not significantly associated with the development of LONIPCs in our series.
Six (60%) of the patients had died at a median follow-up of 13 months (range, 1-50 months) after the diagnosis of LONIPCs. The causes of death were respiratory failure associated with LONIPCs progression in four patients and relapse of underlying diseases in the other two. Figure 1 shows the OS rates of patients with and without LONIPCs. The 5-year OS rate was significantly lower among patients with, than without LONIPCs (28.0 vs 87.2%, P ¼ 0.000). Among 43 patients with malignant diseases, the relapse rates between those with and without LONIPCs did not significantly differ (33 vs 25%, P ¼ 0.98). Among the 12 patients with malignant diseases and chronic GVHD, two of the four with LONIPCs relapsed compared with none of those without LONIPCs.
Discussion
We retrospectively evaluated the incidence, risk factors and clinical outcome of LONIPCs in pediatric patients and found that the incidence of LONIPCs in this population was similar to that among adults. 10, 11 On the other hand, Schultz et al. 15 reported a higher incidence of BO (19.4%) in a pediatric, compared with an adult series. They considered that the most plausible explanation was that children have smaller airways than adults. However, the incidence of BO in their study was higher than in the present (8.2%) and in other pediatric studies. 6, 22 One explanation for the difference between the findings of Schultz and our results is the high incidence of chronic GVHD in their study, which is a strong risk factor for BO. The incidence of chronic GVHD was 52% in their study, whereas that of our study was only 30%. Therefore, Table 3 Risk factors associated with late-onset non-infectious pulmonary complications Non-infectious pulmonary complication in children N Nishio et al reducing the incidence of chronic GVHD may lead to fewer late-onset pulmonary complications. Our multivariate analysis identified high-risk underlying disease and extensive chronic GVHD as independent risk factors for LONIPCs. Patients with high-risk underlying disease might develop cryptic lung injury caused by chemotherapeutic agents before transplantation, which would render them vulnerable to allo-immune reactions. The toxicity of chemotherapeutic conditioning regimens may also be a cause of LONIPCs. In fact, conditioning with reduced doses is associated with a lower rate of BO and other pulmonary complications. 23, 24 None of the patients developed LONIPCs after undergoing reduced-intensity regimens in the present study. However, the number of patients on reduced-intensity regimens was too small to reach statistical significance.
Although the pathogenesis of LONIPCs has not been clarified in detail, considerable evidence supports the notion that allo-immune reactions are involved. 25, 26 Several reports showed that the development of LONIPCs is associated with the presence of chronic GVHD. Our multivariate analysis also showed a close relationship between the development of LONIPCs and extensive chronic GVHD. We experienced a patient who developed chronic GVHD and subsequent typical BO after donor lymphocyte infusion for the treatment of relapse. Studies of several murine models have shown that hostreactive donor T lymphocytes can cause lung injury that mimics LONIPCs, 26, 27 which also indicates that alloimmune reactions are involved in the pathogenesis of LONIPCs.
The OS rate was significantly worse among patients with, than those without LONIPCs in our study, which is consistent with the results of a recent large cohort study.
11
On the other hand, Sakaida et al. 10 found that the OS rates between patients with or without LONIPCs were identical because of the lower relapse rate of underlying malignant diseases in patients with LONIPCs. Their data suggested a powerful GVL effect in patients with LONIPCs. However, the relapse rates of the underlying malignant diseases did not differ between patients regardless of LONIPCs in our study. None of the six patients with chronic GVHD but without LONIPCs relapsed, whereas two of the six with both chronic GVHD and LONIPC relapsed. A larger patients cohort is required to draw conclusions about this issue.
The response rate to corticosteroids among patients with BOOP is favorable, 13 but quite low in patients with BO or IPS.
1,9,28-30 Fullmer et al. 31 recently described an 8-year-old girl with BO confirmed by biopsy who was unresponsive to corticosteroid, but who was successfully treated with infliximab. Inhaled steroids and long-acting bronchodilators have shown promising results in a group of patients with mild to moderately severe BO. 32 We also administered inhaled steroids and bronchodilators to three BO patients according to the literature. All patients improved clinically and their symptoms of dyspnea disappeared, but pulmonary function test values were not affected. Patient 8 was classified as non-responder at 4 weeks after the start of steroid inhalation, but continued steroid inhalation and remained stable for more than 1 year. Long-term steroid inhalation may be warrented even for non-responders at the time of evaluation.
In conclusion, 10% of the pediatric patients developed LONIPCs after allogeneic hematopoietic SCT and their prognosis were extremely poor. Considering that we are lacking optimal therapies for LONIPCs, strategies aimed at prevention of LONIPCs should be attempted.
